Human Patents (Class 435/366)
  • Patent number: 11491485
    Abstract: The present application relates to a microfluidic system and its method for use for the separation of motile sperm from immotile sperm or motile bacteria from immotile bacteria. The system includes a housing having a first end, and a second end, with a passage connecting the first and second ends. There is an inlet at the first end of the housing for charging fluids into the passage and an outlet at the second end of said housing for discharging fluids from the passage. There are one or more corrals within the passage, each of the corrals including a closed side and a partially open side. The closed side of the corrals is closer to the first end than the partially open side, with the closed side and partially open side defining between them a confinement region suitable for retaining motile sperm or motile bacteria.
    Type: Grant
    Filed: April 3, 2019
    Date of Patent: November 8, 2022
    Assignee: CORNELL UNIVERSITY
    Inventors: Alireza Abbaspourrad, Meisam Zaferani, Soon Hon Cheong
  • Patent number: 11464808
    Abstract: A tissue construct is provided that comprises a pancreas derived microvessel fragment and a pancreatic islet cell. The pancreas derived microvessel fragment and the pancreatic islet cell can be incorporated into a biocompatible medium. Tissue constructs can be comprised of other cells, such as stem cells, combined with the pancreas derived microvascular fragment. Methods for isolating microvessel fragments from a pancreas are also provided and include enzymatic digestion of pancreatic tissue and separation of microvessel fragments from endocrine and exocrine tissue. Methods for treating diabetes are further provided and include administration of the tissue constructs.
    Type: Grant
    Filed: April 27, 2018
    Date of Patent: October 11, 2022
    Assignee: University of Louisville Research Foundation
    Inventors: Balamurugan Appakalai, Stuart K. Williams
  • Patent number: 11446332
    Abstract: Provided herein are methods and compositions for dynamically controlling and targeting multiple immunosuppressive mechanisms in cancer. Some aspects provide cells engineered to produce multiple effector molecules, each of which modulates a different immunosuppressive mechanisms of a tumor, as well as methods of using the cells to treat cancer, such as ovarian, breast, or colon cancer.
    Type: Grant
    Filed: April 13, 2018
    Date of Patent: September 20, 2022
    Assignee: SENTI BIOSCIENCES, INC.
    Inventors: Timothy Kuan-Ta Lu, Russell Morrison Gordley, Jack Tzu-Chiao Lin, Brian Scott Garrison, Philip Janmin Lee, Alba Gonzalez-Junca, Don-Hong Wang
  • Patent number: 11427805
    Abstract: Disclosed herein are cell cultures comprising dorsal and/or ventral PDX1-positive foregut endoderm cells and methods of producing the same. Also disclosed herein are cell populations comprising substantially purified dorsal and/or ventral PDX1-positive foregut endoderm cells as well as methods for enriching, isolating and purifying dorsal and/or ventral PDX1-positive foregut endoderm cells from other cell types. Methods of identifying differentiation factors capable of promoting the differentiation of dorsal and/or ventral PDX1-positive foregut endoderm cells, are also disclosed.
    Type: Grant
    Filed: November 26, 2018
    Date of Patent: August 30, 2022
    Assignee: ViaCyte, Inc.
    Inventors: Kevin Allen D'Amour, Alan D. Agulnick, Susan Eliazer, Emmanuel E. Baetge
  • Patent number: 11419916
    Abstract: This disclosure relates to compositions and methods for recruiting brown adipocytes in vitro and in vivo from brown adipocyte progenitor cells found in human skeletal muscle. Methods for treating metabolic disease are also provided. Additionally, methods for treating hypothermia are provided. In some embodiments, the brown adipocyte recruiter is a human protein or peptide. In other embodiments the brown adipocyte recruiter may be a non-human protein or peptide. In still other embodiments, the brown adipocyte recruiter is a small molecule or natural product.
    Type: Grant
    Filed: February 24, 2015
    Date of Patent: August 23, 2022
    Assignee: ENERGESIS PHARMACEUTICALS, INC.
    Inventor: Olivier D. Boss
  • Patent number: 11382931
    Abstract: Described herein are methods for selecting lymphocytes for adoptive cell therapy based on P-glycoprotein expression and compositions comprising same.
    Type: Grant
    Filed: July 14, 2017
    Date of Patent: July 12, 2022
    Assignee: University of Southern California
    Inventor: Preet M. Chaudhary
  • Patent number: 11369642
    Abstract: The present invention provides a method for lowering blood glucose levels in an animal by transplanting a population of pancreatic endocrine precursor cells into an animal.
    Type: Grant
    Filed: August 13, 2019
    Date of Patent: June 28, 2022
    Assignee: Janssen Biotech, Inc.
    Inventor: Jean Xu
  • Patent number: 11364321
    Abstract: A scaffold-free microtissue is disclosed that includes one or more gold nanostructures linked to a functional moiety, wherein the functional moiety is one or more vasculogenic peptides, one or more anti-inflammatory peptides, one or more antiapoptotic peptides, one or more antinecrotic peptides, one or more antioxidant peptides, one or more oligonucleotides, one or more lipid particles, one or more phospholipid particles, one or more liposomes, one or more nanoliposomes, one or more microRNAs, or one or more siRNAs. The scaffold-free microtissue further includes a plurality of cardiac myocytes or cardiac myoblasts, which are conjugated to the one or more gold nanostructures, wherein the plurality of cardiac myocytes or cardiac myoblasts are arranged in a cluster.
    Type: Grant
    Filed: October 11, 2018
    Date of Patent: June 21, 2022
    Assignees: Arizona Board of Regents on Behalf of Arizona State University, The United States of America as Represented by The Department of Veterans Affairs
    Inventors: Mehdi Nikkhah, Ali Navaei, Raymond Migrino
  • Patent number: 11345891
    Abstract: The present disclosure relates to compositions, nucleic acid constructs, methods and kits thereof for cell induction or reprogramming cells to the dendritic cell state or antigen presenting cell state, based, in part, on the surprisingly effect described herein of novel use and combinations of transcription factors that permit induction or reprogramming of differentiated or undifferentiated cells into dendritic cells or antigen presenting cells. Such compositions, nucleic acid constructs, methods and kits can be used for inducing dendritic cells in vitro, ex vivo, or in vivo, and these induced dendritic cells or antigen presenting cells can be used for immunotherapy applications.
    Type: Grant
    Filed: April 5, 2018
    Date of Patent: May 31, 2022
    Assignee: Asgard Therapeutics AB
    Inventors: Carlos Filipe Ribeiro Lemos Pereira, Cristiana Ferreira Pires, Fabio Alexandre Fiuza Rosa
  • Patent number: 11339371
    Abstract: Provided in the present invention is a method for inducing pluripotent stem cells to differentiate into ventricular myocytes in vitro, which is achieved by maintaining, amplifying and culturing pluripotent stem cells in vitro, adding a substance capable of activating the Smad1/5/8 signaling pathway directly or indirectly into the culture medium when pluripotent stem cells are in the middle stage of myocardial differentiation, i.e. the period of differentiating into cardiac muscle cells from mesoderm cells or myocardial precursor cells, which enables stem cells to differentiate into ventricular myocytes directionally.
    Type: Grant
    Filed: July 22, 2013
    Date of Patent: May 24, 2022
    Assignee: INSTITUTE OF BIOPHYSICS, CHINESE ACADEMY OF SCIENCES
    Inventor: Yue Ma
  • Patent number: 11318225
    Abstract: Thin parylene C membranes having smooth front sides and ultrathin regions (e.g., 0.01 ?m to 5 ?m thick) interspersed with thicker regions are disclosed. The back sides of the membranes can be rough compared with the smooth front sides. The membranes can be used in vitro to grow monolayers of cells in a laboratory or in vivo as surgically implantable growth layers, such as to replace the Bruch's membrane in the eye. The thin regions of parylene are semipermeable to allow for proteins in serum to pass through, and the thick regions give mechanical support for handling by a surgeon. The smooth front side allows for monolayer cell growth, and the rough back side helps prevents cells from attaching there.
    Type: Grant
    Filed: June 16, 2016
    Date of Patent: May 3, 2022
    Assignees: California Institute of Technology, University of Southern California
    Inventors: Yu-Chong Tai, Bo Lu, Mark Humayun
  • Patent number: 11299714
    Abstract: A cardiac organoid containing 3-D matter of adult human heart tissue.
    Type: Grant
    Filed: May 11, 2016
    Date of Patent: April 12, 2022
    Assignee: The Trustees of Columbia University in The City of New York
    Inventors: Gordana Vunjak-Novakovic, Keith Yeager, Kacey Ronaldson, Stephen Ma, Timothy Chen
  • Patent number: 11299749
    Abstract: Disclosed is an expression regulatory system for cell-specific transcription (expression) of a protein of interest, for example a cell cycle inducer that reactivates proliferation in adult or neonatal cardiomyocytes or insulin-producing beta cells. The expression regulatory system comprises a first nucleic acid that encodes a microRNA recognition element that specifically binds a target cell miR, and a translation suppressor protein; and a second nucleic acid that comprises a suppressor protein interaction motif that binds the translation suppressor protein, and a gene that encodes a protein of interest. When a cell of interest is co-transfected with the first and second nucleic acids of the system, the protein of interest expressed in a cell-specific fashion.
    Type: Grant
    Filed: March 15, 2019
    Date of Patent: April 12, 2022
    Assignee: ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
    Inventors: Lior Zangi, Ajit Magadum
  • Patent number: 11291756
    Abstract: A method for separating cells in a biofluid includes pretreating the biofluid by introducing an additive comprising a cell activator, flowing the pretreated biofluid through a microfluidic separation channel, and applying acoustic energy to the microfluidic separation channel to accumulate target cells in a primary stream and non-target cells in a secondary stream. A system for microfluidic cell separation capable of separating target cells from non-target cells in a biofluid includes at least one microfluidic separation channel, a source of biofluid, a source of additive comprising a cell activator, and at least one acoustic transducer coupled to the microfluidic separation channel.
    Type: Grant
    Filed: June 25, 2019
    Date of Patent: April 5, 2022
    Assignee: THE CHARLES STARK DRAPER LABORATORY, INC.
    Inventors: Jason O. Fiering, Kenneth T. Kotz, Nathan Francis Moore
  • Patent number: 11287427
    Abstract: In spite of significant efforts to identify ?-cell-specific markers for ?-cell imaging and purification, progress has been limited. Herein is disclosed a novel biomarker of human pancreatic ?-cells, CD39L3 (also known as ectonucleoside triphosphate diphosphohydrolase-3 (NTPDase3)). Disclosed are compositions and methods for purifying and imaging ?-cell using anti-CD39L3 antibodies.
    Type: Grant
    Filed: June 11, 2018
    Date of Patent: March 29, 2022
    Assignees: VANDERBILT UNIVERSITY, THE UNITED STATES AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS
    Inventors: Alvin C. Powers, Marcela Brissova, Chunhua Dai, Neil Phillips, Diane Saunders
  • Patent number: 11278573
    Abstract: Compositions and methods are provided for repairing damaged avascular zones, including intervertebral disc, in a patient in need thereof.
    Type: Grant
    Filed: June 14, 2019
    Date of Patent: March 22, 2022
    Assignee: REGENEXX, LLC
    Inventor: Christopher J. Centeno
  • Patent number: 11268059
    Abstract: Apparatuses, systems, and methods are provided for culturing a buoyant target tissue. Embodiments include a first surface configured to culture a first layer of supporting cells, and a second surface configured to culture a second layer of supporting cells. The first layer of supporting cells may be formed on a portion of the first surface and the second layer of supporting cells may be formed on a portion of the second surface. The buoyant target tissue may be added to the first layer of supporting cells. The second layer of supporting cells may be placed on the first layer of supporting cells such that the buoyant target tissue is sandwiched between the first layer of supporting cells and second layer of supporting cells.
    Type: Grant
    Filed: June 28, 2019
    Date of Patent: March 8, 2022
    Assignee: EXO CELL, LLC
    Inventors: Frank Ho Pak Lau, Steven Douglas Scahill
  • Patent number: 11254911
    Abstract: Provided herein are isolated neural stem cells. Also provided are methods for treatment of neurodegenerative diseases using suitable preparations comprising the isolated neural stem cells.
    Type: Grant
    Filed: November 29, 2016
    Date of Patent: February 22, 2022
    Assignee: ACCELERATED BIOSCIENCES CORP.
    Inventors: Jau-Nan Lee, Tony Tung-Ying Lee, Yuta Lee, Eing-Mei Tsai
  • Patent number: 11220672
    Abstract: The present invention relates to chemically defined and xenogeneic material-free methods for deriving endothelial cells from human pluripotent stem cells. In particular, the present invention provides highly efficient and reproducible methods of obtaining human endothelial cells from human pluripotent stem cells, where endothelial cells derived from the methods provided herein are suitable for clinically relevant therapeutic applications.
    Type: Grant
    Filed: December 31, 2015
    Date of Patent: January 11, 2022
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: James A. Thomson, Jue Zhang
  • Patent number: 11207424
    Abstract: This document relates to methods and materials for increasing viral vector infectivity. For example, methods and materials for using spliceosome inhibitors (e.g., U2 snRNP spliceosome inhibitors such as meayamycin B or pladienolide derivative E7107) to increase viral vector (e.g., adeno-associated virus-based vector) infectivity are provided.
    Type: Grant
    Filed: June 12, 2015
    Date of Patent: December 28, 2021
    Assignees: Mayo Foundation for Medical Education and Research, University of Pittsburgh—Of the Commonwealth System of Higher Educat
    Inventors: Yasuhiro Ikeda, Claire A. Schreiber, Toshie Sakuma, Sara J. Holditch, Kazunori Koide
  • Patent number: 11203224
    Abstract: Certain aspects and features relate to using an image modifier to generate digital designs and to printing the digital designs on a structure for flooring or other decoration that can more realistically mimic designs found in nature or otherwise provide designers with the freedom to create aesthetic designs more easily. An image modifier can receive an image, such as an image of a naturally occurring view and generate modified designs based on the image. The modified designs can be slight modifications to the image and printed on the structures for flooring such that together the printed structures exhibit the appearance of a design found in nature or a desired appearance by a designer.
    Type: Grant
    Filed: August 30, 2019
    Date of Patent: December 21, 2021
    Assignee: INTERFACE, INC.
    Inventors: Graeme Robert Ripley, John Proctor Bradford
  • Patent number: 11185069
    Abstract: Embodiments of the present invention relate to methods of preparing a cell, tissue, organ or plant for cryopreservation, wherein the method includes contacting the cell, tissue, organ or plant with a composition including sucrose and/or sucralose.
    Type: Grant
    Filed: May 15, 2019
    Date of Patent: November 30, 2021
    Assignee: East Carolina University
    Inventors: Anthony Kennedy, Jean-Luc Scemama, Jitka Virag, Edward R. Pennington
  • Patent number: 11162070
    Abstract: Provided herein are methods of enriching a retinal pigment epithelium (RPE) cell population derived from stem cells. Such a method may comprise removing contaminating cells through the depletion of CD24 positive cells, CD56 positive cells, and/or CD90 positive cells from a starting population of RPE cells.
    Type: Grant
    Filed: September 7, 2016
    Date of Patent: November 2, 2021
    Assignee: FUJIFILM Cellular Dynamics, Inc.
    Inventors: Nathan Meyer, Lucas Chase, Casey Stankewicz
  • Patent number: 11148465
    Abstract: Certain aspects and features relate to using an image modifier to generate digital designs and to printing the digital designs on a structure for flooring or other decoration that can more realistically mimic designs found in nature or otherwise provide designers with the freedom to create aesthetic designs more easily. An image modifier can receive an image, such as an image of a naturally occurring view and generate modified designs based on the image. The modified designs can be slight modifications to the image and printed on the structures for flooring such that together the printed structures exhibit the appearance of a design found in nature or a desired appearance by a designer.
    Type: Grant
    Filed: August 30, 2019
    Date of Patent: October 19, 2021
    Assignee: Interface, Inc.
    Inventors: Graeme Robert Ripley, John Proctor Bradford
  • Patent number: 11142739
    Abstract: A scaffold-stretching system includes at least one stretchable loading chamber configured to support a scaffold material and a supply of cells, such as human skin substitute cells, and is configured to allow for cultivation of a cellular three-dimensional scaffold; and a mechanical loading system is configured for application of cyclic and static uniaxial tensile mechanical loading on the cellular three-dimensional scaffold, and is configured to mimic the in vivo environment of musculoskeletal, cardiovascular, and other tissues that experience uniaxial strains.
    Type: Grant
    Filed: March 3, 2017
    Date of Patent: October 12, 2021
    Assignee: The University of Toledo
    Inventors: Gayathri Subramanian, Mostafa Elsaadany, Eda Yildirim-Ayan
  • Patent number: 11093787
    Abstract: Methods, apparatuses, systems, and implementations for creating 3-dimensional (3D) representations exhibiting geometric and surface characteristics of brain lesions are disclosed. 2D and/or 3D MRI images of the brain may be acquired. Brain lesions and other abnormalities may be identified and isolated with each lesion serving as a region of interest (ROI). Saved ROI may be converted into stereolithography format, maximum intensity projection (MIP) images, and/or orthographic projection images. Data corresponding to these resulting 3D brain lesion images may be used to create 3D printed models of the isolated brain lesions using 3D printing technology. Analysis of the 3D brain lesion images and the 3D printed brain lesion models may enable a more efficient and accurate way of determining brain lesion etiologies.
    Type: Grant
    Filed: June 30, 2017
    Date of Patent: August 17, 2021
    Assignee: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Darin T Okuda, Braeden D Newton
  • Patent number: 11015171
    Abstract: The purpose of the present invention is to provide immortalized stem cells for producing culture supernatant that can be used in the treatment of human diseases. Provided is a method for producing immortalized stem cells, the method being provided with: a step for producing a DNA fragment that includes a telomerase reverse transcriptase and at least one gene selected from the group consisting of Bmi-1, human papilloma virus E6, and human papilloma virus E7; a step for producing a viral vector that incorporates the DNA fragment including the gene; a step for transfecting the viral vector into mammalian stem cells and introducing the gene into the stem cells; and a step for culturing the stem cells into which the gene was introduced and using a drug to select immortalized stem cells.
    Type: Grant
    Filed: May 1, 2018
    Date of Patent: May 25, 2021
    Assignee: QUARRYMEN & Co. Inc.
    Inventor: Yasuhiro Yamashita
  • Patent number: 11001802
    Abstract: The present invention relates to the field of mammalian cell culture, and provides methods and compositions for cell attachment to, cultivation on and detachment from a solid substrate surface containing from at least about 0.5% N, a sum of O and N of greater than or equal to 17.2% and a contact angle of at least about 13.9 degrees, lacking a feeder cell layer and lacking an adlayer. In one embodiment of the present invention, the cells are treated with a compound capable of inhibiting Rho kinase activity. In another embodiment, the cells are treated with a compound capable of inhibiting Rho activity.
    Type: Grant
    Filed: August 31, 2018
    Date of Patent: May 11, 2021
    Assignee: Nunc A/S
    Inventors: Benjamin Fryer, Shelley Nelson, Villy Nielsen, Tina Kristensen Marwood, Thomas Brevig
  • Patent number: 10988518
    Abstract: The present invention provides a method for producing a ? myosin heavy chain in cardiac muscle cells differentiated from induced pluripotent stem cells derived from Homo sapiens. In the present method, first, a liquid culture medium containing the cardiac muscle cells is supplied onto a substrate comprising a first electrode, a second electrode and insulative fibers on the surface thereof. At least a part of the insulative fibers is located between the first electrode and the second electrode in a top view of the substrate. Then, the substrate is left at rest. Finally, the cardiac muscle cells are cultivated, while a pulse electric current is applied to the cardiac muscle cells through the first electrode and the second electrode.
    Type: Grant
    Filed: December 20, 2017
    Date of Patent: April 27, 2021
    Assignee: PANASONIC CORPORATION
    Inventors: Kiyotaka Tsuji, Li Liu
  • Patent number: 10982213
    Abstract: The present invention discloses an siRNA that inhibits K-RAS gene expression, and the precursor sequences and applications thereof. The K-RAS siRNA and its precursor sequences provided by the present invention can efficiently inhibit the expression of the K-RAS gene, and in vivo experiments have shown that the K-RAS siRNA has a certain inhibitory effect on tumours highly expressing K-RAS. The precursor of the siRNA of the invention and its vector can form a stable siRNA that functions in a host.
    Type: Grant
    Filed: May 5, 2017
    Date of Patent: April 20, 2021
    Assignee: JIANGSU MICROMEDMARK BIOTECH CO., LTD.
    Inventors: Chenyu Zhang, Xi Chen, Hongwei Liang, Uzair Ur-Rehman, Ke Zeng
  • Patent number: 10968429
    Abstract: Culture media, which contain chelated iron, promote cell proliferation of neural stem cells and/or neural progenitor cells while maintaining undifferentiated state and multipotency.
    Type: Grant
    Filed: September 28, 2017
    Date of Patent: April 6, 2021
    Assignee: AJINOMOTO CO., INC.
    Inventors: Takuya Matsumoto, Sho Senda, Tsuyoshi Kobayashi, Akihiro Arakawa
  • Patent number: 10968435
    Abstract: The invention provides an automated system for producing induced pluripotent stem cells (iPSCs) from adult somatic cells. Further, the system is used for producing differentiated adult cells from stem cells.
    Type: Grant
    Filed: April 29, 2019
    Date of Patent: April 6, 2021
    Assignee: New York Stem Cell Foundation, Inc.
    Inventors: Scott Noggle, Kevin C. Eggan, Stephen Chang, Susan L. Solomon
  • Patent number: 10953048
    Abstract: The present disclosure relates to the acceleration of hematopoietic compartment reconstitution in a subject in need of hematopoietic stem cell transplantation by administering a composition having a protein transduction domain-MYC (PTD-MYC) fusion protein in combination with hematopoietic stem cell transplantation and to the enhancement of hematopoietic compartment autoreconstitution in a subject in need thereof by administering a composition having a protein transduction domain-MYC (PTD-MYC) fusion protein.
    Type: Grant
    Filed: January 29, 2019
    Date of Patent: March 23, 2021
    Assignee: TAIGA BIOTECHNOLOGIES, INC.
    Inventors: Brian C. Turner, Yosef Refaeli, Gregory Alan Bird
  • Patent number: 10947490
    Abstract: A liquid delivery device includes a first and second container for a first and second liquid; a third container for receiving a first and second liquid; a fourth container into which a first and second liquid are discharged; a fifth container for a third liquid; a first liquid delivery tube for delivering a first liquid; a second liquid delivery tube for delivering a second liquid; a third liquid delivery tube connected to the first and second liquid delivery tube; a first liquid delivery pump on the third liquid delivery tube; a fourth liquid delivery tube for discharging a first liquid contained in the third container and delivering a third liquid to the third container; a fifth liquid delivery tube connected to the fourth liquid delivery tube; a sixth liquid delivery tube connected to the fourth liquid delivery tube; and a second liquid delivery pump on the fourth liquid delivery tube.
    Type: Grant
    Filed: February 14, 2018
    Date of Patent: March 16, 2021
    Assignee: HITACHI, LTD.
    Inventors: Hikaru Saito, Masaharu Kiyama, Midori Kato, Kunio Ohyama, Guangbin Zhou, Hiroko Hanzawa, Shizu Takeda
  • Patent number: 10947502
    Abstract: Provided herein are methods for the efficient in vitro differentiation of somatic cell-derived pluripotent stem cells to hematopoietic precursor cells, and the further differentiation of the hematopoietic precursor cells into immune cells of various myeloid or lymphoid lineages, particularly T cells, NK cells, and dendritic cells. The pluripotent cells may be maintained and differentiated under defined conditions; thus, the use of mouse feeder cells or serum is not required in certain embodiments for the differentiation of the hematopoietic precursor cells.
    Type: Grant
    Filed: October 20, 2016
    Date of Patent: March 16, 2021
    Assignee: FUJIFILM Cellular Dynamics, Inc.
    Inventors: Maksym A. Vodyanyk, Xin Zhang, Andrew J. Brandl, Deepika Rajesh, Bradley Swanson, Christie Munn, Sarah A. Burton, Wen Bo Wang
  • Patent number: 10935542
    Abstract: Variations in the differentiation and lineage potential of stem cells, including mesenchymal stem cells, currently limit their therapeutic use. The ability to identify, isolate, and specifically amplify stem cell populations with desired differentiation potential would contribute the use of stem cells in research and therapy. The present invention discloses a method of assessing differentiation potential of stem cells by measuring the differential expression of antigens CD 146 and NG2 on the stem cells. The correlation between CD 146 and NG2 expression and differentiation and trilineage potential is explored. The invention also discloses methods to specifically amplify or enrich stem cells with desired differentiation potential, monitor the differentiation potential of a heterogeneous stem cell population, quantify the heterogeneity in differentiation potential of a stem cell culture, and remove stem cells with specific differentiation potentials from a heterogeneous cell culture.
    Type: Grant
    Filed: December 21, 2011
    Date of Patent: March 2, 2021
    Assignee: THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND OFFICE OF TECHNOLOGY TRANSFER AND INTELLECTUAL PROPERTY DEVELOPMENT
    Inventors: Kim O'Connor, Katie Russell
  • Patent number: 10918707
    Abstract: The invention pertains to the use of VirB10 to immunize a host against an infection by a bacterium having T4SS. The invention provides a vaccine comprising VirB10, a fragment of VirB10, a polynucleotide encoding VirB10 or a polynucleotide encoding a fragment of VirB10 and a pharmaceutically acceptable carrier and/or adjuvant. The invention also provides a method of immunizing a host against an infection caused by a bacterium having T4SS, the method comprising administering to the host a vaccine of the invention. The vaccines and the methods of the invention can be used to immunize against infections caused by bacteria having T4SS in dogs, rabbits, cats, pigs, cattle, sheep, goats, deer, horses, rodents and humans.
    Type: Grant
    Filed: June 16, 2016
    Date of Patent: February 16, 2021
    Assignee: University of Florida Research Foundation, Incorporated
    Inventors: Anthony F. Barbet, Francy L. Crosby
  • Patent number: 10913931
    Abstract: A method of preparing viable stromal and mesenchymal stem cells from adipose tissue that produces high quality and high counts of stem cells with a low risk of contamination. The apparatus provides ultrasonic waves through a constant temperature bath to the tissue held in a sterile sonication container such as a test tube or jar. No sonication probe touches the tissue or the cells during the process. The stem cells produced are ready to be administered to a patient.
    Type: Grant
    Filed: January 26, 2018
    Date of Patent: February 9, 2021
    Inventor: Glenn Polansky
  • Patent number: 10844354
    Abstract: This disclosure generally concerns the fields of cell biology and molecular biology. In particular the invention concerns the field of stem cell biology and maturation of stem cell-derived cardiomyocytes. Disclosed is a method for improving the maturity of stem-cell derived cardiomyocytes, in particular of the ventricular type, as can be witnessed by, for example, an improved upstroke velocity of the stem-cell derived cardiomyocytes.
    Type: Grant
    Filed: June 5, 2015
    Date of Patent: November 24, 2020
    Assignee: NCARDIA B.V.
    Inventors: Stefan Robbert Braam, Leon Tertoolen, Christine Mummery
  • Patent number: 10815480
    Abstract: Disclosed herein are antisense compounds and methods for decreasing alpha-synuclein mRNA and protein expression. Also disclosed herein are methods for treating, preventing, and ameliorating neurodegenerative diseases in an individual in need thereof.
    Type: Grant
    Filed: April 18, 2017
    Date of Patent: October 27, 2020
    Assignee: Ionis Pharmaceuticals, Inc.
    Inventor: Susan M. Freier
  • Patent number: 10808224
    Abstract: The present invention provides a method of obtaining aggregates containing a rostral hypothalamus tissue and a rostral head ectodermal tissue, a hypophysis precursor tissue and a hypophysis hormone producing cell, by using a serum-free medium (preferably substantially free of growth factor and insulins), forming homogeneous aggregates of stem cells from pluripotent stem cells such as ES cell and the like, which are plated at a high cell concentration, and subjecting the formed aggregates to floating-culture.
    Type: Grant
    Filed: October 31, 2012
    Date of Patent: October 20, 2020
    Assignees: RIKEN, Sumitomo Chemical Company, Limited
    Inventors: Yoshiki Sasai, Hidetaka Suga
  • Patent number: 10787640
    Abstract: Methods are provided for the generation of mesodermal cell types and derivatives thereof. Also provided are methods for generating purified populations of mesodermal cell types and derivatives thereof. The instant disclosure also provides methods of screening for cellular responses of the generated mesodermal cell types and derivatives thereof. Also provide are methods for screening for organismal phenotypes induced by introduction of the generated mesodermal cell types and derivatives thereof. Treatment methods making use of the generated mesodermal cell types and derivatives thereof are also provided. The instant disclosure also provides systems, compositions, and kits for practicing the methods of the disclosure.
    Type: Grant
    Filed: March 2, 2016
    Date of Patent: September 29, 2020
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Kyle Ming Loh, Irving L. Weissman, Lay Teng Ang, Angela Chen
  • Patent number: 10774234
    Abstract: The present invention is to provide a cell culture vessel comprising a copolymer which contains a recurring unit containing an organic group of the following formula (a) and a recurring unit containing an organic group of the following formula (b) being coated onto a surface thereof, a method for manufacturing the same and a method for manufacturing a cell aggregate using the same (wherein Ua1, Ua2, Ub1, Ub2 and Ub3, and An? are as defined in the present specification and the claims).
    Type: Grant
    Filed: June 9, 2014
    Date of Patent: September 15, 2020
    Assignee: NISSAN CHEMICAL INDUSTRIES, LTD.
    Inventors: Ayako Otani, Taito Nishino, Yoshiomi Hiroi, Takahiro Kishioka, Tomoyuki Ozawa
  • Patent number: 10760053
    Abstract: The present disclosure provides a method of manufacturing and differentiating mammalian stem cells, and in one embodiment human induced pluripotent stem cells (iPSc), e.g., manufacturing neuron progenitors, e.g., derived from iPSC, on a large scale by the use of an automated hollow fiber reactor system. In one embodiment, human iPSc that can be differentiated into cardiomyocytes or neuron progenitors are provided. The method comprises seeding a hollow fiber reactor with stem cells such as iPSc, or differentiated iPSc, growing and expanding the seeded cells using appropriate growth factors and nutrients, and harvesting the cells after expansion from the hollow fiber reactor walls, e.g., with the use of an enzyme. The method can produce billions of cells per week from seeding the reactor with a minimum number of starting stem cells or neuron progenitor cells.
    Type: Grant
    Filed: October 14, 2016
    Date of Patent: September 1, 2020
    Assignee: StemoniX Inc.
    Inventor: Robert John Petcavich
  • Patent number: 10760048
    Abstract: Methods and systems for generating MGE precursor cells in vitro as well as compositions of enriched MGE precursor cells are provided. The methods and systems provide efficient production of MGE precursors. The methods and systems disclosed herein provide functional MGE precursors which differentiate into functional GABAergic interneurons.
    Type: Grant
    Filed: September 10, 2018
    Date of Patent: September 1, 2020
    Assignee: The Regents of the University of California
    Inventors: Cory R. Nicholas, John L. Rubenstein, Arnold R. Kriegstein, Arturo Alvarez-Buylla
  • Patent number: 10743996
    Abstract: There are disclosed compositions for achieving reverse phase characteristics, methods of preparation thereof, and the use of amniotic tissue for cartilage repair. In an embodiment, a biocompatible articular tissue repair composition may have a therapeutic material and a carrier configured for achieving reverse phase characteristics, and methods for using the composition. In various embodiments, the therapeutic material may be amniotic tissue. In various embodiments, the carrier may be a poloxamer such as poloxamer 407. Other embodiments are also disclosed.
    Type: Grant
    Filed: March 26, 2018
    Date of Patent: August 18, 2020
    Inventor: Robert L. Bundy
  • Patent number: 10704043
    Abstract: Optimized inhibitory nucleic acids are provided. The nucleic acids have sequences which include an optimal inhibitory motif, such as a GGG. Related methods are also described.
    Type: Grant
    Filed: January 14, 2016
    Date of Patent: July 7, 2020
    Assignee: Exicure, Inc.
    Inventors: Weston Daniel, Scott Mix
  • Patent number: 10704025
    Abstract: The present invention provides methods to promote the differentiation of pluripotent stem cells into insulin producing cells. In particular, the present invention provides a method to produce cells expressing markers characteristic of the pancreatic endocrine lineage that co-express NKX6.1 and insulin and minimal amounts of glucagon.
    Type: Grant
    Filed: March 13, 2017
    Date of Patent: July 7, 2020
    Assignee: Janssen Biotech, Inc.
    Inventor: Jean Xu
  • Patent number: 10655098
    Abstract: The embodiments of the invention described herein relate to systems and methods for culturing and/or maintaining intestinal cells, tissues and/or organoids in vitro. The cells, tissues and/or organoids cultured according to the methods and systems described herein can mimic or reproduce natural intestinal epithelial structures and behavior as well as support co-culture of intestinal microflora.
    Type: Grant
    Filed: February 28, 2012
    Date of Patent: May 19, 2020
    Assignee: PRESIDENT AND FELLOWS OF HARVARD COLLEGE
    Inventors: Donald E. Ingber, Hyun Jung Kim
  • Patent number: 10655100
    Abstract: The present invention relates to a method of inducing the differentiation of human pluripotent stem cell-derived embryoid bodies into ectoderm by CXCR2 stimulation, and more particularly, to a method of promoting the differentiation of human pluripotent stem cell-derived embryoid bodies into ectoderm by stimulating and activating the surface receptor CXCR2 of the embryoid bodies with the CXCR2-specific ligand GRO-?. The method of inducing the differentiation of human pluripotent stem cell-derived embryoid bodies into ectoderm by CXCR2 stimulation according to the present invention can increase the efficiency and utility of stem cells as a cell therapeutic agent, because it promotes the differentiation of stem cells into a specific germ layer serving as the origin of target cells, which is the first important step for inducing the differentiation of stem cells into specific cells.
    Type: Grant
    Filed: November 10, 2015
    Date of Patent: May 19, 2020
    Assignee: KOREA UNIVERSITY RESEARCH AND BUSINESS FOUNDATION
    Inventors: Byung Soo Kim, Ji-Hye Jung, Yong Park